Development and prospective validation of a Frailty Score for chemotherapy associated toxicity in Relapsed Ovarian Cancer - FraStrROC

OGGO e.V.0 个研究点目标入组 408 人开始时间: 2018年10月17日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients must provide written informed consent prior to performance of study specific assessments and must be willing to comply with recommended treatment and follow up assessments.
•Able to complete questionnaires independently.
•Women aged = 18 years
•Histologically confirmed diagnosis of epithelial ovarian cancer or carcinosarcoma (EOC), primary peritoneal carcinoma (PPC) or fallopian tube cancer (FTC).
•Patients must have recurrent cancer disease (CA 125, radiological or clinical signs of recurrence or progression).
•Patients recommended for monochemotherapy with either Paclitaxel, PLD, Topotecan or Treosulfan and with optional use of bevacizumab according decision of the treating physician and following approval and who should start therapy within 2 week of registration in this trial.
•At least 1 prior treatment regimen for ovarian cancer (i.e. up from second line treatment is allowed)
•Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3
•A life expectancy of at least 12 weeks.

•Patients recommended for combination chemotherapy or under maintenance treatment after prior chemotherapy, or planned only for radiation therapy.
•Chemotherapy or radiation therapy or tumour embolization within 2 weeks prior to registration and study assessment.
•Biological therapy, immunotherapy, hormonal therapy or treatment with an investigational agent within 21 days.
•Any unstable or serious concurrent condition (e.g. active infection requiring systemic therapy).
•Legal incapacity or limited legal capacity
•Medical or psychological conditions that would not permit the subject to complete the study assessments or sign informed consent

发起方

OGGO e.V.